Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24571838 | 1.00 | LMNA (0.58) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL3537584 | 1.00 | LMNA (0.58) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL6870509 | 0.87 | LMNA (0.60) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL3534384 | 0.84 | LMNA (0.55) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL3529851 | 0.84 | LMNA (0.55) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL25529105 | 0.83 | LMNA (0.56) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL24011654 | 0.82 | HDAC1 (0.62) | LMNARAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL9386998 | 0.81 | LMNA (0.55) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL3409275 | 0.81 | LMNA (0.66) | LMNARAB9ASMN1; SMN2NAPRTMDM4 | |
| SCHEMBL9391489 | 0.80 | LMNA (0.54) | LMNARAB9ASMN1; SMN2NAPRTMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654235-B1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-7838540-B2 | 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | SIMITHKLINE BEECHMAN CORPORATION (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1654235-A1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005014550-A1 | 3- AMINOCARBONYL, 6-PHENYL SUBSTITUTED PYRIDINE-1-OXIDES AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161684-A1 | 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors | MAPK1, MAPK3, MAPKAPK2 | LMNA 3072/4885RAB9A 1054/4885SMN1; SMN2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.